Clinical Trials Logo

Clinical Trial Summary

This is a pilot study to determine the utility of Novel Functional Lung Imaging and Ventilation (4DxV) Analysis software in measurement of lung ventilation abnormalities and diagnosis of chronic lung allograft dysfunction (CLAD) after lung transplantation.


Clinical Trial Description

This is a pilot study to determine the feasibility and utility of Novel Functional Lung Imaging and Ventilation (4DxV) Analysis software in measurement of lung ventilation abnormalities and diagnosis of CLAD after lung transplantation. 4DxV is a technology developed by 4Dx (4Dx Limited, Melbourne, Australia and Los Angeles, CA) and is a novel computational approach to the data obtained from standard fluoroscopic imaging that measures tissue motion of the lung at all locations and in all phases of breath. These motion measurements are used to calculate 4-dimensional ventilation (4DxV) of lung tissue to provide variety of outputs. The investigators will establish the sensitivity, specificity, and accuracy of this technology in diagnosis of CLAD compared to CT scan and pulmonary function results in patients with a known diagnosis of CLAD based on established diagnostic criteria. The investigators will test the following hypotheses: 1. 4DxV scans will be able to detect quantitative ventilation abnormalities in patients with established CLAD and the severity of the abnormalities will correlate with severity of PFT decline 2. 4DxV will be able to diagnose patients with CLAD of the bronchiolitis obliterans syndrome (BOS) phenotype grades 0 (CLAD free) vs grades 1-3 ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04892719
Study type Interventional
Source Duke University
Contact
Status Completed
Phase N/A
Start date October 28, 2020
Completion date March 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05526950 - Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb) N/A
Recruiting NCT05916495 - An Evaluation of Remote Care (Questionnaire+Hybrid) in Patients Who Are Post-lung Transplant N/A
Enrolling by invitation NCT05950724 - RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant Early Phase 1
Active, not recruiting NCT05505422 - Routine Versus Selective Intraoperative ECMO in Lung Transplant N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Enrolling by invitation NCT04522388 - Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant N/A
Completed NCT04165161 - Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography N/A
Recruiting NCT05050955 - AlloSure Lung Assessment and Metagenomics Outcomes Study
Withdrawn NCT03258801 - Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
Completed NCT03221764 - Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients Phase 2
Active, not recruiting NCT04975607 - Live Music Therapy to Reduce Anxiety, Pain and Improve Sleep in Post-Operative Lung Transplant Patients: A Pilot Study N/A
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT03367221 - Physiological Response in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist N/A
Recruiting NCT03276403 - Primary Graft Dysfunction Score in Lung Transplantation N/A
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT05242289 - Cytokine Adsorption in Lung Transplantation N/A
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Not yet recruiting NCT04377139 - Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)
Not yet recruiting NCT06399302 - Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
Terminated NCT03562416 - Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects Phase 2